Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jul 2, 2018- Company invests €66 million in Chengdu, Sichuan province, China-
Jun 25, 2018- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin
-
Jun 4, 2018-- Patients treated with cemiplimab experienced robust anti-tumor effects
-
May 21, 2018* In steroid-sparing VENTURE trial, Dupixent-treated patients substantially reduced use of oral corticosteroids, yet had fewer exacerbations and improved lung function compared to placebo.
-
May 16, 2018* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
-
May 1, 2018-- Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation
